



GP 1656

INFORMATION DISCLOSURE STATEMENT CHECKLIST

Client and Matter Name: _____ PG 100

Client #/ Matter #: 082440/00002

Attorney and Due Date Pabst _____

Check Requested N/A _____

I have checked the following sources for references to be cited in the IDS and/or
Supplemental IDS:

RECEIVED

Application and PTO Correspondence File

SEP 25 2002

Application

TECH CENTER 1600/2900

IDS/ Supp. IDS

Office Action/ PTO-892

Other _____


PCT File

PCT Written Opinion

International Search Report

Other PG 100 European Search Report [G&C folder]

Suggestions/Requests for other sources:


Erica C. Boughner



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#5
RECEIVED

Applicants: Abraham J. Domb

SEP 25 2002

Serial No.: 10/044,538

Art Unit: 1636

TECH CENTER 1600/2900

Filed: January 10, 2002

Examiner: Not Yet Assigned

For: **CATIONIC POLYSACCHARIDE COMPOSITIONS**

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits an Information Disclosure Statement, including two (2) pages of Form PTO-1449 and copies of twenty-three documents cited therein.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

U.S. Patents

| <u>Number</u> | <u>Issue Date</u> | <u>Patentee</u> | <u>Class/Subclass</u> |
|---------------|-------------------|------------------|-----------------------|
| 3,225,012 | 12-21-1965 | Black, et al. | 260/78 |
| 4,146,515 | 03-27-1979 | Buikema et al. | 260/9 |
| 5,312,967 | 05-17-1994 | Kieley, et al. | 560/180 |
| 5,329,044 | 07-12-1994 | Kieley, et al. | 562/564 |
| 5,434,233 | 07-18-1995 | Kieley, et al. | 527/310 |
| 5,473,035 | 12-05-1995 | Kieley, et al. | 527/312 |
| 5,833,230 | 11-10-1998 | Nakagawa, et al. | 271/121 |

INFORMATION DISCLOSURE STATEMENT

Foreign Documents

| <u>Number</u> | <u>Publication Date</u> | <u>Patentee</u> | <u>Country</u> |
|---------------|-------------------------|---------------------------|----------------|
| WO 95/30020 | 12-09-1995 | Immuno-Designed Molecules | PCT |
| WO 97/46223 | 12-11-1997 | Genzyme Corporation | PCT |
| WO 98/27209 | 06-25-1998 | Emory University | PCT |
| WO 01/07486 | 02-01-2001 | Polygene, Ltd. | PCT |
| 0 370 810 | 11-23-1989 | Nippon Oil and Fats Co. | EP |

Publications

BYK & SCHERMAN *Exp. Opin. Ther.* 8(9): 1125-1141 (1998).

DOMB, *et al.*, "Polymers in gene therapy," in Frontiers in Biological Polymer Applications (Ottenbrite, ed.) Technomic: Lancaster, Vol. 2, pp. 1-16 (1999).

KIELY, *et al.*, "Hydroxylated nylons based on unprotected esterified D-glucaric acid by simple condensation reactions," *J. Am. Chem. Soc.* 116: 571-578 (1994).

LEDLEY, "Nonviral gene therapy: The promise of genes as pharmaceutical products," *Human Gene Therapy* 6: 1129-1144 (1995).

LEE, *et al.*, "Self aggregates of hydrophobically modified chitosan for DNA delivery," *Proceed Intl. Symp. Control. Rel. Bioact. Matter* 24: 651-652 (1997).

MAO, *et al.*, "DNA-chitosan nanospheres: derivitization and storage stability," *Proc. Intl. Symp. Control Rel. Bioact. Matter* 24: 671-672 (1997).

RICHARDSON, *et al.*, "Evaluation of highly purified chitosan as a potential gene delivery vector," *Proceed Intl. Symp. Control Rel. Bioact. Matter* 24: 649-650 (1997).

TAKAKURA, *et al.*, "Control of pharmaceutical properties of soybean tyrosine inhibitor by conjugation with dextran 1: synthesis and characterization," *J. Pharm. Sci.* 78(2): 117-121 (1999).

TRECO & SELDEN, "Non viral gene therapy," *Molec. Med. Today* 1(7):299-348 (1995).

WALSH, *et al.*, "Combination of drug and gene delivery by gelatin nanospheres for the treatment of cystic fibrosis," *Proc. Intl. Sym. Control. Rel. Bioact. Mater.* 24: 75-76 (1997).

YAMAOKA, *et al.*, "Effect of cation content of polycation-type gene carriers on *in vitro* gene transfer," *Chemistry Letters*, 1171-1172 (1998).

U.S.S.N.: 10/044,538

Filed: January 10, 2002

INFORMATION DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst

Reg. No. 31,284

Dated: September 20, 2002

HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588

U.S.S.N.: 10/044,538


Filed: January 10, 2002

INFORMATION DISCLOSURE STATEMENT

Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: September 20, 2002



The image shows a handwritten signature in black ink. The signature appears to read "Erica C. Roughner". Below the signature, the name "Erica C. Roughner" is printed in a smaller, sans-serif font.

ATL1 #526728 v1